Affimed Therapeutics

Affimed Therapeutics

Verified
NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies.

Launch date
Employees
Market cap
$78.0m
Net debt
$36.2m
Enterprise valuation
$42m (Public information from Jul 2024)
Company register number HRB 721206 (Mannheim)
Heidelberg Baden-Württemberg (HQ)

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR2019202020212022202320242025
Revenues0000000000000000000000000000
% growth(16 %)33 %42 %2 %(80 %)(38 %)16 %
EBITDA0000000000000000000000000000
% EBITDA margin(145 %)(121 %)(159 %)(210 %)(1255 %)--
Profit0000000000000000000000000000
% profit margin(151 %)(146 %)(143 %)(208 %)(1280 %)--
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue205 %176 %202 %239 %1148 %--
  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor investor investor investor

$0.0

round
investor

$0.0

round
N/A

$0.0

round
investor

$0.0

round
investor

$0.0

round
N/A

$0.0

round
*
N/A

$90.0m

Post IPO Equity
Total Funding000k

Recent News about Affimed Therapeutics

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo